obesity pill outweighs ozempic injection

DrShivago

Sep 14, 2024

1 min read

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill, amycretin, at the European Association for the Study of Diabetes meeting in Madrid.

Recent Posts

See All

Oral GLP

Oral GLP-1 drugs are likely to expand the market massively The more disruptive development may actually be oral agents. Many patients are willing to take a pill but reluctant to self-inject indefinite

GLP medication with an expanding spectrum of indications

Eli Lilly licensed global rights, excluding South Korea, to Hanmi Pharm's investigational long-acting GLP-2 analogue sonefpeglutide across multiple indications, under a deal potentially worth around $

Novi and Eli Lilly in fierce competition

Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly PUBLISHED TUE, MAR 31 20267:39 AM EDTUPDATED TUE, MAR 31 20262:10 PM EDT Annika Kim Cons

Comments